logo
Twitter
Discord
Email
logo
IQVIA Holdings Inc.

IQVIA Holdings Inc.

NYSE•IQV
CEO: Mr. Ari Bousbib
Sector: Healthcare
Industry: Medical - Diagnostics & Research
Listing Date: 2013-05-09
IQVIA Holdings Inc. engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; strategic planning and design services; and patient and site centric solutions, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company has a collaboration with argenx SE; and a strategic collaboration with NVIDIA Corporation. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. The company is headquartered in Durham, North Carolina.
Contact Information
2400 Ellis Road, Durham, NC, 27703, United States
919-998-2000
www.iqvia.com
Market Cap
$37.85B
P/E (TTM)
29.5
35.6
Dividend Yield
--
52W High
$234.30
52W Low
$134.65
52W Range
88%
Rank35Top 21.9%
5.0
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Average • 5 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2015-2024

Financial Dashboard

Q3 2025 Data

Revenue

$4.10B+5.24%
4-Quarter Trend

EPS

$1.94+23.57%
4-Quarter Trend

FCF

$1.20B+110.33%
4-Quarter Trend

2025 Q3 Earnings Highlights

Key Highlights

Revenue Growth Strong Total revenues reached $11.95B USD for nine months, marking a 4.4% increase over prior year period.
Operating Cash Flow Rises Cash provided by operating activities totaled $1.92B USD for nine months, increasing $88M compared to 2024.
R&D Backlog Expansion Research & Development Solutions contracted backlog grew to $32.4B USD as of September 30, 2025, expecting $8.1B conversion soon.
Debt Issuance Completed Issued $2.0B in 6.250% Senior Notes due 2032 to repay revolving credit borrowings and fund corporate needs.

Risk Factors

Net Income Declines Net income attributable to IQVIA Holdings Inc. fell to $846M USD for nine months, down $90M from $936M in 2024.
Segment Profit Pressure Total segment profit decreased $43M USD for nine months, reflecting margin compression across core operational areas.
Increased Cost of Revenues Cost of revenues (excl. D&A) grew 6.6% constant currency for nine months, slightly outpacing revenue growth.
Restructuring Costs Incurred $81M restructuring costs recorded for nine months due to ongoing global streamlining and capacity alignment efforts.

Outlook

Share Repurchase Authorization $13.73B total authorization; $1.98B remains available as of September 30, 2025 after $1.03B spent YTD.
Future Revenue Recognition Approximately $34.4B of revenues expected from remaining performance obligations, mostly recognized over the next five years.
Debt Maturity Management Repaid Euro denominated 2.875% Senior Notes due 2025 during the quarter, managing debt maturity profile proactively.
New Tax Disclosure Assessment Assessing impacts of ASU 2023-09 regarding income tax disclosures, effective for annual periods beginning January 1, 2025.

Peer Comparison

Revenue (TTM)

Cardinal Health, Inc.CAH
$234.31B
+4.5%
Humana Inc.HUM
$126.36B
+9.9%
IQVIA Holdings Inc.IQV
$15.90B
+3.8%

Gross Margin (Latest Quarter)

BeiGene, Ltd.ONC
86.1%
+3.1pp
ResMed Inc.RMD
61.5%
+2.9pp
Mettler-Toledo International Inc.MTD
59.2%
+1.1pp

Key Metrics

Symbol
Market Cap
P/E (TTM)
ROE (TTM)
Debt to Assets
CAH$47.09B29.6-55.0%16.4%
INSM$42.02B-35.2-183.6%31.6%
A$39.61B30.320.6%26.4%

Long-Term Trends

Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
1.2%
Moderate Growth
4Q Net Income CAGR
-8.8%
Declining Profitability
Cash Flow Stability
100%
Strong Cash Flow

Research & Insights

Next earnings:Feb 5, 2026
|
EPS:$3.40
|
Revenue:-
Reports
All Years
  • Form 10-Q - Q3 2025

    Period End: Sep 30, 2025|Filed: Oct 28, 2025|
    Revenue: $4.10B+5.2%
    |
    EPS: $1.94+23.6%
    Miss
  • Form 10-Q - Q2 2025

    Period End: Jun 30, 2025|Filed: Jul 22, 2025|
    Revenue: $4.02B+5.3%
    |
    EPS: $1.55-22.1%
    Miss
  • Form 10-Q - Q1 2025

    Period End: Mar 31, 2025|Filed: May 6, 2025|
    Revenue: $3.83B+2.5%
    |
    EPS: $1.42-10.1%
    Miss
  • Form 10-K - FY 2024

    Period End: Dec 31, 2024|Filed: Feb 13, 2025|
    Revenue: $15.41B+2.8%
    |
    EPS: $7.57+2.4%
    Miss
  • Form 10-Q - Q3 2024

    Period End: Sep 30, 2024|Filed: Oct 31, 2024|
    Revenue: $3.90B+4.3%
    |
    EPS: $1.57-5.4%
    Miss
  • Form 10-Q - Q2 2024

    Period End: Jun 30, 2024|Filed: Jul 22, 2024|
    Revenue: $3.81B+2.3%
    |
    EPS: $1.99+23.6%
    Miss
  • Form 10-Q - Q1 2024

    Period End: Mar 31, 2024|Filed: May 2, 2024|
    Revenue: $3.74B+2.3%
    |
    EPS: $1.58+1.3%
    Miss
  • Form 10-K - FY 2023

    Period End: Dec 31, 2023|Filed: Feb 15, 2024|
    Revenue: $14.98B+4.0%
    |
    EPS: $7.39+27.0%
    Miss